/ONC
ONC Stock - BeOne Medicines Ltd.
Healthcare|Medical - PharmaceuticalsNASDAQ
$316.05+2.94%
+$9.03 (+2.94%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.58
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+26.9%upside
Target: $401.07
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$312.89 – $319.21
TARGET (TP)$401.00
STOP LOSS$290.77
RISK/REWARD1:3.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$385.22
52W Low$172.67
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.81B | $2.46B | $1.42B | $1.18B | $308.87M |
| Gross Profit | $3.22B | $2.08B | $1.13B | $1.01B | $238.22M |
| Gross Margin | 84.4% | 84.5% | 79.8% | 86.0% | 77.1% |
| Operating Income | $-568,199,000 | $-1,207,736,000 | $-1,789,665,000 | $-1,438,735,000 | $-1,657,682,000 |
| Net Income | $-644,786,000 | $-881,708,000 | $-2,003,815,000 | $-1,457,816,000 | $-1,624,974,000 |
| Net Margin | -16.9% | -35.9% | -141.5% | -123.9% | -526.1% |
| EPS | $-6.12 | $-8.45 | $-19.37 | $-15.21 | $-19.11 |
Company Overview
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$339
Average Target
↑ 7.3% Upside
Now
$312
Low
$339
Average
$385
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| September 18th 2025 | Barclays | Initiation | Overweight | $385 |
| April 7th 2025 | RBC Capital Mkts | Initiation | Outperform | $312 |
| March 3rd 2025 | BofA Securities | Upgrade | Buy | $320← $207 |
Earnings History & Surprises
ONCBeat Rate
67%
Last 6 quarters
Avg Surprise
+58.4%
EPS vs Estimate
Beats / Misses
4/2
Last 12 quarters
Latest EPS
$1.09
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
+45.2%
$-1.15vs$-2.10
Q4 24
-30.7%
$-1.15vs$-0.88
Q1 25
-62.5%
$-1.43vs$-0.88
Q2 25
+271.8%
$1.22vs$-0.71
Q3 25
+75.0%
$0.84vs$0.48
Q4 25
+51.4%
$1.09vs$0.72
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $1.71 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.72 | $1.09 | +51.4% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.48 | $0.84 | +75.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.71 | $1.22 | +271.8% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.88 | $-1.43 | -62.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.88 | $-1.15 | -30.7% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-2.10 | $-1.15 | +45.2% | ✓ BEAT |
Q1 2024 | Mar 31, 2024 | — | $-2.41 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-25.53 | — | — |
Q3 2023 | Sep 30, 2023 | — | $2.01 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-3.64 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-3.34 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-30.54 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-5.39 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-5.56 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-4.24 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-6.16 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-4.46 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-5.23 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.69 | — | — |
Latest News
BeOne Medicines Wins FDA Fast Track Designation for Experimental Liver Cancer Treatment
📈 PositiveBenzinga•Dec 18, 2025, 11:06 AM
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features
📈 PositiveBenzinga•Dec 7, 2025, 11:03 PM
BeOne Medicines Receives US FDA Priority Review For Sonrotoclax In Relapsed Or Refractory Mantle Cell Lymphoma After BTK Inhibitor Therapy
📈 PositiveBenzinga•Nov 26, 2025, 11:05 AM
Truist Securities Initiates Coverage On BeOne Medicines with Buy Rating, Announces Price Target of $400
📈 PositiveBenzinga•Nov 24, 2025, 05:52 PM
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $408
📈 PositiveBenzinga•Nov 18, 2025, 03:29 PM
BeOne Medicines shares are trading higher after the company announced top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA with or without PD-1 inhibitor TEVIMBRA, as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction, and esophagus.
📈 PositiveBenzinga•Nov 17, 2025, 05:08 PM
Citigroup Maintains Buy on BeOne Medicines, Raises Price Target to $405
📈 PositiveBenzinga•Nov 10, 2025, 09:31 PM•Also:
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $395
📈 PositiveBenzinga•Nov 7, 2025, 06:17 PM
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $396
📈 PositiveBenzinga•Nov 7, 2025, 01:58 PM
BeOne Medicines Raises FY2025 Sales Guidance from $5.000B-$5.300B to $5.100B-$5.300B
➖ NeutralBenzinga•Nov 6, 2025, 11:02 AM
BeiGene Q3 Adj. EPS $2.65 Beats $0.80 Estimate, Sales $1.412B Beat $1.354B Estimate
📈 PositiveBenzinga•Nov 6, 2025, 11:01 AM
Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $383
📈 PositiveBenzinga•Oct 20, 2025, 03:25 PM
Beone Medicines Announced The Presentation Of Data From Two Pivotal Phase 3 Trials – Rationale-307 And 312 – Offering New Evidence Of The Benefits Of Its Pd-1 Inhibitor, Tevimbra (Tislelizumab), At The European Society Of Medical Oncology 2025 Congress In Berlin, Germany, October 17-21
📈 PositiveBenzinga•Oct 20, 2025, 10:10 AM
The FDA Has Granted Breakthrough Therapy Designation To BeOne Medicines' Sonrotoclax, An Investigational BCL2 Inhibitor, For Relapsed Or Refractory Mantle Cell Lymphoma
📈 PositiveBenzinga•Oct 13, 2025, 10:02 AM
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $385
📈 PositiveBenzinga•Oct 8, 2025, 05:33 PM•Also:
Barclays Initiates Coverage On BeOne Medicines with Overweight Rating, Announces Price Target of $385
📈 PositiveBenzinga•Sep 18, 2025, 11:18 AM•Also:
Market-Moving News for September 2nd
➖ NeutralBenzinga•Sep 2, 2025, 11:23 AM•Also: ,
BeOne Medicines shares are trading higher after the company last week announced topline results from a Phase 1/2 study of sonrotoclax in adult patients with relapsed/refractory mantle cell lymphoma, following treatment with a Bruton's tyrosine kinase inhibitor and anti-CD20 therapy.
📈 PositiveBenzinga•Sep 2, 2025, 11:12 AM
BeOne Medicines shares are trading higher after the company announced topline results from a Phase 1/2 study of sonrotoclax in adult patients with relapsed/refractory mantle cell lymphoma, following treatment with a Bruton's tyrosine kinase inhibitor and anti-CD20 therapy.
📈 PositiveBenzinga•Aug 29, 2025, 12:39 PM
BeOne Medicines' Sonrotoclax Achieves ORR In Phase 1/2 R/R Mantle Cell Lymphoma; Global Filings, China NDA Reviews, Phase 3 Ongoing
📈 PositiveBenzinga•Aug 29, 2025, 10:05 AM
Frequently Asked Questions about ONC
What is ONC's current stock price?
BeOne Medicines Ltd. (ONC) is currently trading at $316.05 per share. The stock has moved +2.94% today.
What is the analyst price target for ONC?
The average analyst price target for ONC is $401.00, based on 1 analyst.
What sector is BeOne Medicines Ltd. in?
BeOne Medicines Ltd. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is ONC's market cap?
BeOne Medicines Ltd. has a market capitalization of $33.77 billion, making it a large-cap company.
Does ONC pay dividends?
No, BeOne Medicines Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$137.24
Mkt Cap: $38.9B
ALC
Alcon Inc.
$79.97
Mkt Cap: $39.6B
GEHC
GE HealthCare Technologies Inc.
$82.89
Mkt Cap: $37.9B
HUM
Humana Inc.
$259.40
Mkt Cap: $31.2B
INSM
Insmed Incorporated
$174.84
Mkt Cap: $37.3B
IQV
IQVIA Holdings Inc.
$220.66
Mkt Cap: $37.6B
MTD
Mettler-Toledo International Inc.
$1402.51
Mkt Cap: $28.7B
NTRA
Natera, Inc.
$231.96
Mkt Cap: $32.0B
PHG
Koninklijke Philips N.V.
$26.66
Mkt Cap: $25.4B
RMD
ResMed Inc.
$244.94
Mkt Cap: $35.9B
Explore stocks similar to ONC for comparison